Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_4
2
40%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 42 (40.0%)

Trials by Status

not_yet_recruiting120%
completed360%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_1

A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

NCT07484893
completedphase_2

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
completedphase_4

Subcutaneous Rehydration Compared to Intravenous Rehydration

NCT00773175
completedphase_4

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

NCT00656370
terminatedphase_1

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

NCT01928030

Clinical Trials (5)

Showing 5 of 5 trials
NCT07484893Phase 1

A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

Not Yet Recruiting
NCT01485796Phase 2

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Completed
NCT00773175Phase 4

Subcutaneous Rehydration Compared to Intravenous Rehydration

Completed
NCT00656370Phase 4

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Completed
NCT01928030Phase 1

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5